Treatment Of inoperable carcinoma Merkel cells and / or metastatic By somatostatin analogue - National Multicenter Study Single-arm Phase II [Traitement Des Carcinomes à Cellules de Merkel inopérables et/ou métastatiques Par Analogue de la Somatostatine - Etude Nationale Multicentrique Mono-bras de Phase II]

Trial Profile

Treatment Of inoperable carcinoma Merkel cells and / or metastatic By somatostatin analogue - National Multicenter Study Single-arm Phase II [Traitement Des Carcinomes à Cellules de Merkel inopérables et/ou métastatiques Par Analogue de la Somatostatine - Etude Nationale Multicentrique Mono-bras de Phase II]

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms PHRC-Merkel
  • Most Recent Events

    • 31 Aug 2017 Status changed from recruiting to completed.
    • 12 Aug 2015 Planned End Date changed from 1 Feb 2018 to 1 Apr 2019 as per ClinicalTrials.gov .
    • 12 Aug 2015 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2019 as per ClinicalTrials.gov .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top